Veracyte (VCYT) CFO reports 7,234-share tax withholding, not a sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported a Form 4 transaction involving company common stock. On March 2, 2026, 7,234 shares were withheld at a price of $36.01 per share to cover tax obligations tied to vesting restricted stock units and, as the disclosure notes, this does not represent a sale. After this tax-withholding disposition, Chambers directly owns 149,537 shares of Veracyte common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chambers Rebecca
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 7,234 | $36.01 | $260K |
Holdings After Transaction:
Common Stock — 149,537 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Veracyte (VCYT) report for Rebecca Chambers?
Veracyte reported that CFO Rebecca Chambers had 7,234 common shares withheld on March 2, 2026 to satisfy tax withholding obligations from vesting restricted stock units. The company states this withholding does not represent an open-market sale of shares.
Does the Veracyte CFO’s Form 4 reflect a sale of VCYT stock?
The filing specifically notes the transaction does not represent a sale. The 7,234 shares reported were withheld by Veracyte to satisfy Rebecca Chambers’ tax withholding obligations associated with vesting restricted stock units on March 2, 2026.
What does transaction code F mean in the Veracyte CFO Form 4?
Transaction code F indicates shares were used to pay an exercise price or tax liability. In this case, 7,234 Veracyte shares were withheld to satisfy Rebecca Chambers’ tax obligations on vesting restricted stock units, and the filing clarifies this does not constitute a sale.